menu
    • menu
    [{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Financing","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"UTILITY therapeutics \/ AMR Action Fund","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ AMR Action Fund"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"UTILITY therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Acquisition","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"UTILITY therapeutics \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"UTILITY therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"UTILITY therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Benova (Tianjin) Innovative Medicine Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Benova (Tianjin) Innovative Medicine Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Benova (Tianjin) Innovative Medicine Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Benova (Tianjin) Innovative Medicine Research \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Pivmecillinam

    Menu

    Pivmecillinam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Alembic Pharmaceuticals Limited

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.

                            Details : Alembic will expand their U.S. commercial portfolio with FDA-approved Pivya (pivmecillinam) for the treatment of women with uncomplicated urinary tract infections.

                            Product Name : Pivya

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            July 03, 2025

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Alembic Pharmaceuticals Limited

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves New Treatment for Uncomplicated Urinary Tract Infections

                            Details : Pivya (pivmecillinam) oral tablets are FDA-approved for uncomplicated UTIs in adult females caused by susceptible E. coli, Proteus mirabilis, and Staphylococcus saprophyticus.

                            Product Name : Pivya

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 24, 2024

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : AMR Action Fund

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Utility Therapeutics Ltd. Announces Financing Led By AMR Action Fund and FDA Acceptance

                            Details : Proceeds develop and commercialize European-approved antibiotics Pivya (pivmecillinam), an oral prodrug of mecillinam, and mecillinam, an intravenous (IV) formulation for UTIs.

                            Product Name : Pivya

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : AMR Action Fund

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Benova (Tianjin) Innovative Medicine Research

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Benova (Tianjin) Innovative Medicine Research

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infectio...

                            Details : Pivmecillinam HCl is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 19, 2022

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UTILITY Therapeutics to Present Data at IDWeek 2021

                            Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended spectrum beta-lactamases.

                            Product Name : Pivya

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UTILITY therapeutics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UTILITY Therapeutics Preparing NDA Submission

                            Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases.

                            Product Name : Pivya

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 15, 2021

                            Lead Product(s) : Pivmecillinam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth